多西他赛在肝癌介入化疗中的近期疗效评价(3)
| 第1页 |
参见附件。
[4] 周际昌.实用肿瘤内科学[M].2版，北京：人民卫生出版社，2007：6-9.
[5] 冯晓峰，郑永志，周春柳，等.重组人p53腺病毒注射液在原发性肝癌介入化疗中的应用价值[J].世界华人消化杂志，2013，21(15)：1437-1441.
[6] Grove CS，Lee YC. Vascular endothelial growth factor the key mediator in plelural effusion formation [J].Curr Opin Pulm Med，2002，8(4)：294-301.
[7] Jemal A，Bray F，Center MM，et al. Global cancer statistics[J].CA Cancer J Clin，2011，61(2)：69-90.
[8] Chan SL，Mo FK，Johnson PJ，et al.New utility of an old marker：serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotheraphy[J].J Clin Oncol，2009，27(3)：446-452.
[9] Mizukoshi E，Nakamoto Y，Arai K，et al. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma[J]. Int J Cancer，2010，126(9)：2164-2174.
[10] Nakamoto Y，Kaneko S. Dendritic cell-based immunotherapy for hepatocellular carcinoma[J].Gan To Kagaku Ryoho，2010，37(3)：413-416.
[11] Nagano H.Treatment of advanced hepatocellular carcinoma：intraarterial infusion chemotherapy combined with interferon[J].Oncology，2010，78(Suppl 1)：142-147.
[12] Nakamoto Y，Mizukoshi E，Kitahara M，et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization[J].Clin Exp Immunol，2011， 163(2)：165-177.
[13] Poggi G，Montagna B，Melchiorre F，et al.Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma[J].Anticancer Res，2011，31(11)：3927-3933.
(收稿日期：2013-08-27 本文编辑：魏玉坡)
您现在查看是摘要介绍页，详见PDF附件。